FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
SOUTH PLAINFIELD, N.J. and CHARLOTTE, N.C., Nov. 09, 2016 -- Molecular diagnostics company, Admera Health announced the official launch of OncoGxSelect™ while exhibiting at the Association for Molecular Pathology (AMP) 2016 Annual Meeting in Charlotte, North Carolina. OncoGxSelect™ is a Next Generation Sequencing (NGS)-based test for tumor profiling of common cancer types, assaying 12 genes for mutations that align with well-established national guidelines for molecular testing and therapeutic decision making. The panel genes are: ALK, BRAF, EGFR, ERBB2, KIT, KRAS, MAP2K1, MET, NRAS, PIK3CA, RET and ROS1. Mutations in these genes are frequently the underlying driver of non-small cell lung cancer (NSCLC), melanoma, thyroid, gastrointestinal and breast cancers. Results from OncoGxSelect™ provide targeted therapy recommendations based on gene mutation and tumor type. In addition, relevant, recruiting clinical trials are reported.
OncoGxSelect™ expands Admera’s Oncology Test Portfolio, which also includes OncoGxOne™, a comprehensive 64-gene tumor profiling panel, and PGxOne™ Plus, a pharmacogenomics panel that provides recommendations for over 220 commercial drugs, including cancer, anti-emetic and pain management drugs.
Guanghui Hu, PhD, President and CEO of Admera Health, commented, “The OncoGxSelect™ panel detects clinically actionable mutations that are associated with targeted therapies.” Hu went on to elaborate, “Although Admera already offered comprehensive tumor profiling, with this product launch we can now provide oncologists with a focused panel that follows well-accepted national clinical guidelines.”
Admera Health is exhibiting in Booth #2312 at the AMP 2016 Annual Meeting this week on November 10, 11 and 12.
About Admera Health
Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research use only services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized, medically actionable results.
Admera Health Contact: Brady Millican, VP Business Development 908-222-0533 [email protected]
